Absci Corporation
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Absci Corporation (Nasdaq: ABSI) is a biotechnology company that develops generative AI models and integrated platforms for de novo design of novel proteins, antibodies, and biologics to accelerate drug discovery and development. The company offers its Integrated Drug Creation Platform, which combines generative AI, wet-lab automation, and data sciences; key components include the ABS platform for AI-driven protein design, de novo antibody generation services, and optimization of existing biologics for properties such as developability, stability, and affinity; as well as proprietary datasets and cloud-based software tools for protein engineering. Absci serves pharmaceutical and biotechnology companies targeting oncology, immunology, and metabolic diseases, with operations primarily in the United States and partnerships extending to global markets. Founded in 2011 and headquartered in Vancouver, Washington, the company recently expanded its capabilities through a strategic collaboration with Astellas Pharma in 2024 to co-develop de novo antibodies for an undisclosed target using Absci's generative AI platform; in early 2025, Absci announced a $200 million funding round led by new institutional investors to scale its AI infrastructure and advance multiple programs into preclinical stages; additionally, it launched an upgraded version of its ABS platform featuring enhanced multimodal AI models for faster iteration in therapeutic design.
Company News
Absci Corporation $ABSI Shares Bought by Bank of America Corp DE
Absci to Participate in Upcoming Investor Conferences
AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript
Absci Q2 Earnings Call Highlights
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year?
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript